Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and d… Read more
Praxis Precision Medicines Inc (PRAX) - Total Liabilities
Latest total liabilities as of September 2025: $52.88 Million USD
Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has total liabilities worth $52.88 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Praxis Precision Medicines Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Praxis Precision Medicines Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Praxis Precision Medicines Inc Competitors by Total Liabilities
The table below lists competitors of Praxis Precision Medicines Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Federal Home Loan Mortgage Corp Pref Variable Non Cumulative
OTCQB:FMCCN
|
USA | $3.43 Trillion |
|
Arrow Electronics Inc
NYSE:ARW
|
USA | $22.42 Billion |
|
China Shipbuilding Industry Co Ltd
SHG:601989
|
China | CN¥135.25 Billion |
|
Zurn Elkay Water Solutions Corporation
NYSE:ZWS
|
USA | $1.09 Billion |
|
SM Investments Corporation
PINK:SVTMF
|
USA | $835.46 Billion |
|
Han'S Laser Tech A
SHE:002008
|
China | CN¥19.02 Billion |
|
Hangzhou Chang Chuan Technology Co Ltd
SHE:300604
|
China | CN¥4.92 Billion |
|
Terex Corporation
NYSE:TEX
|
USA | $4.04 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Praxis Precision Medicines Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Praxis Precision Medicines Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Praxis Precision Medicines Inc (2018–2024)
The table below shows the annual total liabilities of Praxis Precision Medicines Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $37.66 Million | +106.03% |
| 2023-12-31 | $18.28 Million | -53.16% |
| 2022-12-31 | $39.02 Million | -6.95% |
| 2021-12-31 | $41.94 Million | +166.76% |
| 2020-12-31 | $15.72 Million | +107.36% |
| 2019-12-31 | $7.58 Million | +47.29% |
| 2018-12-31 | $5.15 Million | -- |